is a Managing Director in Cambridge, MA, USA.
Prior to joining Novartis Venture Fund, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician and worked as a Medical House Officer at Auckland Hospital. He is a Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio, BioNano Genomics, Euthymics, Galera, ImaginAb and Neurovance.
Exits: Akebia Therapeutics, Inc. (NASDAQ: AKBA), Alios BioPharma, Inc. (Acquired by J&J), Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI).
Annexon Neurosciences, Inc. (Board Seat)
BioNano Genomics, Inc. (Board Seat)
Euthymics Bioscience, Inc. (Board Seat)
Galera Therapeutics, Inc. (Board Seat)
ImaginAB, Inc. (Board Seat)
Neurovance, Inc. (Board Seat)